| Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555, 2020 | 1144 | 2020 |
| Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ... Science 373 (6561), 1372-1377, 2021 | 517 | 2021 |
| Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants VV Edara, BA Pinsky, MS Suthar, L Lai, ME Davis-Gardner, K Floyd, ... New England Journal of Medicine 385 (7), 664-666, 2021 | 378 | 2021 |
| Enhanced neonatal Fc receptor function improves protection against primate SHIV infection SY Ko, A Pegu, RS Rudicell, Z Yang, MG Joyce, X Chen, K Wang, S Bao, ... Nature 514 (7524), 642-645, 2014 | 367 | 2014 |
| A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges R Gautam, Y Nishimura, A Pegu, MC Nason, F Klein, A Gazumyan, ... Nature 533 (7601), 105-109, 2016 | 350 | 2016 |
| Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques L Xu, A Pegu, E Rao, N Doria-Rose, J Beninga, K McKee, DM Lord, ... Science 358 (6359), 85-90, 2017 | 307 | 2017 |
| Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo RS Rudicell, YD Kwon, SY Ko, A Pegu, MK Louder, IS Georgiev, X Wu, ... Journal of virology 88 (21), 12669-12682, 2014 | 306 | 2014 |
| Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques PL Lin, S Pawar, A Myers, A Pegu, C Fuhrman, TA Reinhart, SV Capuano, ... Infection and immunity 74 (7), 3790-3803, 2006 | 285 | 2006 |
| Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clinical & Experimental Immunology 182 (3), 289-301, 2015 | 269 | 2015 |
| Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor A Pegu, Z Yang, JC Boyington, L Wu, SY Ko, SD Schmidt, K McKee, ... Science translational medicine 6 (243), 243ra88-243ra88, 2014 | 252 | 2014 |
| New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency NA Doria-Rose, JN Bhiman, RS Roark, CA Schramm, J Gorman, ... Journal of virology 90 (1), 76-91, 2016 | 242 | 2016 |
| Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants L Wang, T Zhou, Y Zhang, ES Yang, CA Schramm, W Shi, A Pegu, ... Science 373 (6556), eabh1766, 2021 | 189 | 2021 |
| Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques AJ Hessell, JP Jaworski, E Epson, K Matsuda, S Pandey, C Kahl, J Reed, ... Nature medicine 22 (4), 362-368, 2016 | 180 | 2016 |
| Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies C Petrovas, S Ferrando-Martinez, MY Gerner, JP Casazza, A Pegu, ... Science translational medicine 9 (373), eaag2285, 2017 | 159 | 2017 |
| Use of broadly neutralizing antibodies for HIV‐1 prevention A Pegu, AJ Hessell, JR Mascola, NL Haigwood Immunological reviews 275 (1), 296-312, 2017 | 158 | 2017 |
| Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN G Rappocciolo, HR Hensler, M Jais, TA Reinhart, A Pegu, FJ Jenkins, ... Journal of virology 82 (10), 4793-4806, 2008 | 157 | 2008 |
| Human lymphatic endothelial cells express multiple functional TLRs A Pegu, S Qin, BA Fallert Junecko, RE Nisato, MS Pepper, TA Reinhart The Journal of Immunology 180 (5), 3399-3405, 2008 | 150 | 2008 |
| Broadly neutralizing antibodies target the coronavirus fusion peptide C Dacon, C Tucker, L Peng, CCD Lee, TH Lin, M Yuan, Y Cong, L Wang, ... Science 377 (6607), 728-735, 2022 | 132 | 2022 |
| Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1. 529 T Zhou, L Wang, J Misasi, A Pegu, Y Zhang, DR Harris, AS Olia, ... Science 376 (6591), eabn8897, 2022 | 118 | 2022 |
| Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge B Julg, LJ Tartaglia, BF Keele, K Wagh, A Pegu, D Sok, P Abbink, ... Science translational medicine 9 (406), eaal1321, 2017 | 118 | 2017 |
